A phase 1/2 study of ruxolitinib and decitabine in patients with post-myeloproliferative neoplasm acute myeloid leukemia.
Bose P, Verstovsek S, Cortes JE, Tse S, Gasior Y, Jain N, Jabbour EJ, Estrov Z, Alvarado Y, DiNardo CD, Pemmaraju N, Kornblau SM, Kadia TM, Daver NG, Naqvi K, Short NJ, Masarova L, Villareal J, Pierce SA, Nogueras-Gonzalez G, Huang X, Garcia-Manero G, Kantarjian HM, Ravandi F.
Bose P, et al. Among authors: tse s.
Leukemia. 2020 Sep;34(9):2489-2492. doi: 10.1038/s41375-020-0778-0. Epub 2020 Feb 25.
Leukemia. 2020.
PMID: 32099037
Clinical Trial.
No abstract available.